Stephen K. Van Den Eeden

Stephen K. Van Den Eeden

Auto-generated profile, based on publicly available information

Stephen K. Van Den Eeden

Division of Research, Kaiser Permanente Northern California, Oakland, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2003 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
SEStephen K Van Den Eeden
Stephen K Van Den Eeden
CTCaroline M Tanner
Caroline M Tanner
ABAllan L Bernstein
Allan L Bernstein
RFRobin D Fross
Robin D Fross
ALAmethyst Leimpeter
Amethyst Leimpeter
LNLorene M Nelson
Lorene M Nelson
The goal of this study was to estimate the incidence of Parkinson’s disease by age, gender, and ethnicity. Newly diagnosed Parkinson’s disease cases in 1994–1995 were identified among members of the Kaiser Permanente Medical Care Program of Northern California, a large health maintenance organization. Each case met modified standardized criteria/Hughes diagnostic criteria as applied by a movement disorder specialist. Incidence rates per 100,000 person-years were calculated using the Kaiser Permanente membership information as the denominator and adjusted for age and/or gender using the direct method of standardization. A total of 588 newly diagnosed (incident) cases of Parkinson’s disease were identified, which gave an overall annualized age- and gender-adjusted incidence rate of 13.4 per 100,000 (95% confidence interval (CI): 11.4, 15.5). The incidence rapidly increased over the age of 60 years, with only 4% of the cases being under the age of 50 years. The rate for men (19.0 per 100,000, 95% CI: 16.1, 21.8) was 91% higher than that for women (9.9 per 100,000, 95% CI: 7.6, 12.2). The age- and gender-adjusted rate per 100,000 was highest among Hispanics (16.6, 95% CI: 12.0, 21.3), followed by non-Hispanic Whites (13.6, 95% CI: 11.5, 15.7), Asians (11.3, 95% CI: 7.2, 15.3), and Blacks (10.2, 95% CI: 6.4, 14.0). These data suggest that the incidence of Parkinson’s disease varies by race/ethnicity.

4 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DCDavid V. Conti
David V. Conti
BDBurcu F. Darst
Burcu F. Darst
LMLilit C. Moss
Lilit C. Moss
ESEdward J. Saunders
Edward J. Saunders
XSXin Sheng
Xin Sheng
CHChristopher A. Haiman
Christopher A. Haiman

15 December 2022 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
AWA. W. Willis
A. W. Willis
ERE. Roberts
E. Roberts
JBJ. C. Beck
J. C. Beck
BFB. Fiske
B. Fiske
WRW. Ross
W. Ross
JDJames M. Doria
James M. Doria
Parkinson disease (PD) is the second most common age-related neurodegenerative condition diagnosed in North America. We recently demonstrated, using multiple epidemiological data sources, that the prevalence of PD diagnoses was greater than previously reported and currently used for clinical, research, and policy decision-making. Prior PD incidence estimates have varied, for unclear reasons. There is a need for improved estimates of PD incidence, not only for care delivery planning and future policy but also for increasing our understanding of disease risk. The objective of this study was thus to investigate the incidence of Parkinson disease across five epidemiological cohorts in North America in a common year, 2012. The cohorts contained data on 6.7 million person-years of adults ages 45 and older, and 9.3 million person-years of adults ages 65 and older. Our estimates of age-sex-adjusted incidence of PD ranged from 108 to 212 per 100,000 among persons ages 65 and older, and from 47 to 77 per 100,00 among persons ages 45 and older. PD incidence increased with age and was higher among males. We also found persistent spatial clustering of incident PD diagnoses in the U.S. PD incidence estimates varied across our data sources, in part due to case ascertainment and diagnosis methods, but also possibly due to the influence of population factors (prevalence of genetic risk factors or protective markers) and geographic location (exposure to environmental toxins). Understanding the source of these variations will be important for health care policy, research, and care planning.

5 January 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SAStacey Alexeeff
Stacey Alexeeff
NLNoelle S. Liao
Noelle S. Liao
XLXi Liu
Xi Liu
SEStephen K. Van Den Eeden
Stephen K. Van Den Eeden
SSStephen Sidney
Stephen Sidney
Background: Fine particulate matter <2.5 µm in diameter (PM 2.5 ) has known effects on cardiovascular morbidity and mortality. However, no study has quantified and compared the risks of incident myocardial infarction, incident stroke, ischemic heart disease (IHD) mortality, and cerebrovascular mortality in relation to long‐term PM 2.5 exposure. Methods and Results: We sought to quantitatively summarize studies of long‐term PM 2.5 exposure and risk of IHD and stroke events by conducting a review and meta‐analysis of studies published by December 31, 2019. The main outcomes were myocardial infarction, stroke, IHD mortality, and cerebrovascular mortality. Random effects meta‐analyses were used to estimate the combined risk of each outcome among studies. We reviewed 69 studies and included 42 studies in the meta‐analyses. In meta‐analyses, we found that a 10‐µg/m 3 increase in long‐term PM 2.5 exposure was associated with an increased risk of 23% for IHD mortality (95% CI, 15%–31%), 24% for cerebrovascular mortality (95% CI, 13%–36%), 13% for incident stroke (95% CI, 11%–15%), and 8% for incident myocardial infarction (95% CI, −1% to 18%). There were an insufficient number of studies of recurrent stroke and recurrent myocardial infarction to conduct meta‐analyses. Conclusions: Long‐term PM 2.5 exposure is associated with increased risks of IHD mortality, cerebrovascular mortality, and incident stroke. The relationship with incident myocardial infarction is suggestive of increased risk but not conclusive. More research is needed to understand the relationship with recurrent events.

4 September 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SRSara R. Rashkin
Sara R. Rashkin
RGRebecca Graff
Rebecca Graff
LKLinda Kachuri
Linda Kachuri
KTKhanh K. Thai
Khanh K. Thai
SAStacey E. Alexeeff
Stacey E. Alexeeff
JWJohn S. Witte
John S. Witte
Deciphering the shared genetic basis of distinct cancers has the potential to elucidate carcinogenic mechanisms and inform broadly applicable risk assessment efforts. Here, we undertake genome-wide association studies (GWAS) and comprehensive evaluations of heritability and pleiotropy across 18 cancer types in two large, population-based cohorts: the UK Biobank (408,786 European ancestry individuals; 48,961 cancer cases) and the Kaiser Permanente Genetic Epidemiology Research on Adult Health and Aging cohorts (66,526 European ancestry individuals; 16,001 cancer cases). The GWAS detect 21 genome-wide significant associations independent of previously reported results. Investigations of pleiotropy identify 12 cancer pairs exhibiting either positive or negative genetic correlations; 25 pleiotropic loci; and 100 independent pleiotropic variants, many of which are regulatory elements and/or influence cross-tissue gene expression. Our findings demonstrate widespread pleiotropy and offer further insight into the complex genetic architecture of cross-cancer susceptibility.

8 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAlison P Klein
Alison P Klein
BWBrian M. Wolpin
Brian M. Wolpin
HRHarvey A. Risch
Harvey A. Risch
RSRachael Z. Stolzenberg-Solomon
Rachael Z. Stolzenberg-Solomon
EMEvelina Mocci
Evelina Mocci
LALaufey T. Amundadottir
Laufey T. Amundadottir
In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe and the United States combined. To identify common susceptibility alleles, we performed the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4). Here, we find significant evidence of a novel association at rs78417682 (7p12/TNS3, P = 4.35 × 10−8). Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium yields new genome-wide significant loci: rs13303010 at 1p36.33 (NOC2L, P = 8.36 × 10−14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 × 10−10), rs4795218 at 17q12 (HNF1B, P = 1.32 × 10−8), and rs1517037 at 18q21.32 (GRP, P = 3.28 × 10−8). rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA. Expression quantitative trait locus analysis in three independent pancreatic data sets provides molecular support of NOC2L as a pancreatic cancer susceptibility gene.